

## Lipid Management

Adapted from How Sweet It Is! Management of Diabetes: Diabetes Disease State Management

By Mary Lynn McPherson, PharmD, MA, BCPS, CPE

Age	ASCVD	Recommended statin intensity and combination treatment
< 40 years	No	None
	Yes	If LDL-C $\geq$ 70 mg/dl despite maximally tolerated statin dose, consider adding additional LDL-lowering therapy (such as ezetimibe or PCSK9 inhibitor)
$\geq$ 40 years	No	Moderate
	Yes	If LDL-C $\geq$ 70 mg/dl despite maximally tolerated statin dose, consider adding additional LDL-C lowering therapy (such as ezetimibe or PCSK9 inhibitor)

ASCVD Risk Factors include: LDL-C  $\geq$  100 mg/dl, HTN, smoking, chronic kidney disease, albuminuria, family history of premature ASCVD

High-intensity statin therapy (lowers LDL-C by $\geq$ 50%)	Moderate-intensity statin therapy (lowers LDL-C by 30-50%)
Atorvastatin 40-80 mg	Atorvastatin 10-20 mg
Rosuvastatin 20-40 mg	Rosuvastatin 5-10 mg
	Simvastatin 20-40 mg
	Pravastatin 40-80 mg
	Lovastatin 40 mg
	Fluvastatin XL 80 mg
	Pitavastatin 2-4 mg

Resources:

- Diabetes Care 2018;41(Suppl 1):S86-S104